Pharmaceutical companies’ increased focus on recombinant products creates opportunities

company logo

Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) — The “Global Bleeding Disorder Treatment Market by Drug Type, by Disease Type, by Distribution Channel, by End-User by Region, Competition, Forecast and Opportunity, 2027” report has been added to from ResearchAndMarkets.com offer.

The global bleeding disorders treatment market is expected to witness a stable CAGR during the forecast period 2023-2027.

Factors such as increasing patient population, increasing healthcare expenditure by public and private players, and increasing disposable income of middle-class families are driving the global bleeding disorder treatment market.

Ongoing research and development activities and increased interest of pharmaceutical companies in recombinant products are expected to create lucrative growth opportunities for the global bleeding disorder treatment market over the next five years.

However, the limited reimbursement and high cost of using bleeding disorder treatment facilities may hamper the market growth over the forecast period.

Years considered for this report:

Goal of the study:

  • To analyze and forecast the global bleeding disorder treatment market size from 2017 to 2021.

  • Estimate and forecast the global Bleeding Disorders Treatment market size from 2022 to 2027 and the growth rate to 2027.

  • To classify and forecast the global bleeding disorder treatment market based on drug type, disease type, distribution channel, end-user, and regional distribution.

  • To identify the dominant region or segment in the global Bleeding Disorders Treatment Market.

  • Identify drivers and challenges in the global bleeding disorders treatment market.

  • Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the global bleeding disorder treatment market.

  • To identify and analyze the profile of key players operating in the global Bleeding Disorders Treatment Market.

  • To identify the key sustainable strategies adopted by market players in the global Bleeding Disorders Treatment Market.

Key target audience:

  • Bleeding Disorder Treatment Providers, End Users, Service Providers and Other Stakeholders

  • Distributors and Suppliers of Bleeding Disorder Treatment Products and Services and Other Stakeholders

  • Bodies, forums and alliances related to the treatment of bleeding disorders

  • Market research and consulting firms

The study is helpful in providing answers to several critical questions which are important for industry stakeholders such as manufacturers, suppliers, end users etc. besides enabling them to form strategies for investment and capitalize on market opportunities.

Report Scope:

In this report, the global bleeding disorder treatment market has been segmented into the following categories, in addition to industry trends which have also been detailed below:

Market, by drug type:

Market, by disease type:

  • Hemophilia A

  • Hemophilia B

  • von Willebrand disease

  • Others

Market, by distribution channel:

  • Hospital pharmacies

  • Retail pharmacies

  • On line

Market, by end user:

  • Clinics

  • Hospitals

  • Research institutes

  • Others

Market, by region:

  • North America

  • APAC

  • Europe

  • AEM

  • South America

Main topics covered:

1. Product introduction

2. Research methodology

3. Impact of COVID-19 on the Global Bleeding Disorder Treatment Market

4. Executive Summary

5. Voice of the customer

6. Global Bleeding Disorder Treatment Market Outlook

7. North America Bleeding Disorder Treatment Market Outlook

8. Europe Bleeding Disorders Treatment Market Outlook

9. Asia-Pacific Bleeding Disorder Treatment Market Outlook

10. Middle East & Africa Bleeding Disorders Treatment Market Outlook

11. South America Bleeding Disorders Treatment Market Outlook

12. Market dynamics

13. Market trends and developments

14. Competitive Landscape

15. Strategic Recommendations

16. About the publisher and disclaimer

Companies cited

  • Bayer AG

  • Pfizer Inc.

  • Grifols SA

  • Octapharma S.A.

  • Sun Pharmaceuticals Industries Ltd.

  • Ferring Pharmaceuticals SA

  • Amgen Inc.

  • Sanofi SA

  • Baxter International Inc.

  • F. Hoffmann-La Roche Ltd.

  • Takeda Pharmaceuticals Ltd.

  • Novo Nordisk A/S

  • Novartis AG

  • Eli Lilly and Company Ltd.

  • Gilead Sciences Inc.

For more information on this report, visit https://www.researchandmarkets.com/r/3be7m5

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900